Evidence map›Paper›PMID 41049290›Full record

ReviewFrontiers in cell and developmental biology2025

Advancing therapeutic target discovery in pulmonary diseases: evolution and application of space exploration technologies.

Bo Yang, Quan Zheng, Guozheng Li, Bingnan Liao, Zhongxiao Lin, Hao He

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Bo Yang *Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.
Quan Zheng *School of Pharmacy, Macau University of Science and Technology, Macau, China.
Guozheng LiGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.
Bingnan LiaoGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.
Zhongxiao LinGuangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target and Clinical Pharmacology, The NMPA and State Key Laboratory of Respiratory Disease, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, China.
Hao HeShenzhen Longgang Second People's Hospital, Shenzhen, Guangdong, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenetic alterations are associated with various pulmonary diseases. In recent years, the concept of epigenetic inheritance influenced by spatial variations has garnered increasing attention. Alterations in three-dimensional (3D) chromatin architecture have been demonstrated to play a crucial role in regulating gene expression and influencing the pathogenesis and progression of lung-related diseases. Techniques such as high-throughput chromosome conformation capture (Hi-C) have emerged as powerful tools for detecting spatial chromatin conformational changes. In this review, we summarize key targets identified through Hi-C and related methodologies in the context of pulmonary diseases and explore their potential implications for epigenetic therapies.

Indexed as

chromatin structureepigeneticsHi-C technologypulmonary diseasestherapeutic targets

Identifiers

PMID41049290
PMCPMC12488709

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.